A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Raltegravir (Isentress) and Buprenorphine.

Trial Profile

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Raltegravir (Isentress) and Buprenorphine.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2012

At a glance

  • Drugs Buprenorphine/naloxone (Primary) ; Raltegravir (Primary)
  • Indications Opioid abuse
  • Focus Pharmacokinetics
  • Most Recent Events

    • 20 Nov 2012 Primary endpoint amended as reported by ClinicalTrials.gov record.
    • 20 Mar 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 20 Mar 2010 Actual patient number (12) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top